白细胞介素-6抑制药治疗类风湿关节炎的研究进展  

Research Progress on Interleukin-6 Inhibitors in the Treatment of Rheumatoid Arthritis

作　　者：陈玥[1] 

机构地区：[1]中国人民解放军总医院临床药学中心,北京100853

出　　处：《医药导报》2017年第6期646-649,共4页Herald of Medicine

基　　金：中国人民解放军总医院科技创新苗圃基金(16KMM50)

摘　　要：类风湿关节炎(RA)是一种反复发作的慢性炎性自身免疫性疾病,目前还没有很好的根治方法。白细胞介素-6(IL-6)在RA的发病及疾病进展、关节破坏中起重要作用,阻断IL-6已经成为治疗RA的新手段。该文综述以IL-6及其受体为靶的IL-6抑制药,如托珠单抗,sarilumab,ALX-0061,sirukumab,MEDI5117,clazakizumab和olokizumab等在治疗RA中的研究进展。Rheumatoid arthritis（ RA） is a chronic inflammatory disease characterized by polyarthritis. Numerous agents with varying mechanisms are used in the treatment of RA,but there is no radical cure. Interleukin-6（ IL-6） plays an important role in the pathogenesis of RA. Agents targeting IL-6 such as tocilizumab（ TCZ） attracted significant attention as a promising agent in RA treatment. This article reviewed the key efficacy and safety data from clinical trials of TCZ,as well as six candidate IL-6 blockers including sarilumab,ALX-0061,sirukumab,MEDI5117,clazakizumab,and olokizumab,and their future perspectives in the treatment of RA.

关 键 词：托珠单抗 白细胞介素-6抑制药 类风湿关节炎 白细胞介素-6 

分 类 号：R976[医药卫生—药品] R593.22[医药卫生—药学]